TY  - GEN
AU  - Hida,Toyoaki
AU  - Tamiya,Motohiro
AU  - Nishio,Makoto
AU  - Yamamoto,Nobuyuki
AU  - Hirashima,Tomonori
AU  - Horai,Takeshi
AU  - Tanii,Hiromi
AU  - Shi,Michael M
AU  - Kobayashi,Ken
AU  - Horio,Yoshitsugu
TI  - Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer
SN  - 1349-7006
PY  - 2011///0609
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacokinetics
KW  - Asian People
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Carboplatin
KW  - administration & dosage
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Squamous Cell
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Remission Induction
KW  - Survival Rate
KW  - Tissue Distribution
KW  - Treatment Outcome
KW  - Xanthones
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1349-7006.2010.01839.x
ER  -